 aberrant activation of the Janus kinase, JAK, and signal transducer and activator of transcription, stat, pathway is common in systemic lupus erythematosis, SLE. This causes immune mediated properties in target tissues, which can lead to end organ damage. Several cytokines are responsible for this activation, and multiple drugs have been developed to block them. These include tophacetanib, boricetanib, and ducrobacetanib, which have all been used to treat SLE with varying degrees of success. Tophacetanib, a JAK1-3 inhibitor, was found to reduce cholesterol levels, improve vascular function, and decrease the type by interferon signature in SLE patients. Boricetanib, a JAK1-2 inhibitor, showed significant improvement in lupus rashes and arthritis in two separate clinical trials, but these results were not replicated in another trial. Ducrobacetanib, a selective tyrosine kinase 2, TYK2, inhibitor, produced greater response. This article was authored by Dionysus Nicolopoulos, Dionysus Nicolopoulos, Ioannis Parides, and others. We are article.tv, links in the description below.